Anti‑GT1b Monoclonal Antibody – Research Use Only

The Anti‑GT1b Monoclonal Antibody is a biotechnology‑grade reagent targeting the ganglioside GT1b, a sialylated glycosphingolipid enriched in neuronal membranes. GT1b plays key roles in axonal stability, synaptic function, and neuroimmune interactions. This antibody is widely used in neuroimmunology, ganglioside profiling, Guillain‑Barré syndrome (GBS) research, and studies of glycosphingolipid distribution in the central and peripheral nervous systems. Each batch is produced to high purity and supplied as a liquid antibody preparation for reliable performance in analytical and immunological workflows.

Scientific Overview

GT1b is a complex ganglioside highly expressed in neuronal membranes, particularly in the brain and peripheral nerves. Anti‑GT1b antibodies are essential tools for studying ganglioside localization, glycosphingolipid‑mediated signaling, and autoimmune neuropathies. In Guillain‑Barré syndrome and related disorders, anti‑ganglioside antibodies—including anti‑GT1b—are associated with specific clinical presentations and electrophysiological patterns. This monoclonal antibody enables precise detection of GT1b in cells, tissues, and biochemical preparations.

Common Research Applications

• Detection of GT1b ganglioside in neuronal tissues
• Neuroimmunology and autoimmune neuropathy research
• Guillain‑Barré syndrome (GBS) and Miller Fisher syndrome studies
• Ganglioside profiling and glycosphingolipid analysis
• Immunostaining of neuronal membranes
• Biochemical assays involving ganglioside–protein interactions

Usage & Handling Guidance

Store at -80 °C for long‑term stability. Avoid repeated freeze–thaw cycles by aliquoting upon receipt. Thaw gently on ice before use. For best performance, use low‑binding tubes and maintain sterile technique.

• Storage: -80 °C
• Handling: Aliquot to avoid freeze–thaw cycles
• Compatibility: Immunostaining, ELISA, dot blot, ganglioside binding assays

What You Get

• 50 µg Anti‑GT1b Monoclonal Antibody
• High‑purity, biotechnology‑grade reagent
• Batch‑specific documentation available upon request
• For research use only (RUO)

Frequently Asked Questions

• What does this antibody recognize?
  This monoclonal antibody specifically recognizes the ganglioside GT1b, a sialylated glycosphingolipid enriched in neuronal membranes.
• Is this antibody suitable for immunostaining?
  Yes. It is commonly used for immunostaining neuronal tissues, cultured neurons, and ganglioside‑rich membrane preparations.
• Can this antibody be used in Guillain‑Barré syndrome research?
  Yes. Anti‑GT1b antibodies are frequently studied in the context of GBS, Miller Fisher syndrome, and related autoimmune neuropathies.
• Does this antibody cross‑react with other gangliosides?
  Cross‑reactivity is batch dependent and should be evaluated experimentally. Contact us for available specificity data.
• How should the antibody be stored?
  Store at -80 °C. Aliquot upon arrival to avoid freeze–thaw cycles.
• Is this antibody suitable for diagnostic use?
  No. This product is intended strictly for in vitro research use only (RUO).
• Can I request a COA or TDS?
  Yes. COA/TDS availability is batch dependent. Contact us with the catalog and lot number to request documentation.

---

References

• Schnaar RL et al. Anti‑ganglioside antibody binding in differentiating oligodendrocytes. Glycobiology. 1996.
• Boffey J et al. Variable region gene usage in anti‑ganglioside antibodies. J Neuroimmunol. 2005.
• Lunn MP et al. High‑affinity anti‑ganglioside antibodies in knockout mice. J Neurochem. 2000.
• Fan X et al. Antibody responses to glycosphingolipids in knockout mice. Nagoya J Med Sci. 2011.
• Schnaar RL et al. Monoclonal antibodies to major brain gangliosides. Anal Biochem. 2002.
• Saha S, Mondal S. GT1b immunization studies. Indian J Exp Biol. 2000.
• Naik GS et al. Anti‑ganglioside antibodies in GBS. Neurol India. 2017.
• Hsieh PF et al. Anti‑GT1b antibodies after stroke. Kaohsiung J Med Sci. 1998.
• Kinboshi M et al. GBS with anti‑GT1b antibodies. Rinsho Shinkeigaku. 2019.